Cutaneous melanoma in the elderly

Melanoma Research

Volumn 19, Issue 3, 2009, Pages 125-134

  Testori, Alessandro ^a,b   Soteldo, Javier ^a   Sances, Daniele ^a   Mazzarol, Giovanni ^a   Trifirò, Giuseppe ^b   Zonta, Mark ^a   Rastrelli, Marco ^a   Schenone, Francesco ^c   Verrecchia, Francesco ^a  

^a Divisions of Melanoma and Soft Tissue Sarcoma ^*

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; MELPHALAN; TECHNETIUM 99M; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COMORBIDITY; ELECTROCONVULSIVE THERAPY; EPILUMINESCENCE MICROSCOPY; EXCISION; HEREDITY; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MALIGNANT LENTIGO; MELANOMA; METASTASIS; MOLECULAR GENETICS; PALLIATIVE THERAPY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; REVIEW; SENTINEL LYMPH NODE BIOPSY; AGED; LYMPH NODE METASTASIS; PATHOLOGY; SKIN TUMOR;

AGED; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 67849094203     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328329fe95     Document Type: Review

References (133)

1. US Census Bureau. International Database. Washington, DC: US Census Bureau; 2000.
2. Rosenthal RA, Kavic SM. Assessment and management of the geriatric patient. Crit Care Med 2004; 32 (Suppl):S92-S105.
3. Wiener DC, Argote-Green LM, Ramesh H, Audisio RA, Jaklitsch MT. Choices in the management of asymptomatic lung nodules in the elderly. Surg Oncol 2004; 13:239-248.
4. Ramesh HS, Pope D, Gennari R, Audisio RA. Optimizing surgical management of elderly cancer patients. World J Surg Onc 2005; 3:17.
5. Alexander HR, Turnbull AD, Salomone J, Keefe D, Melendez J. Upper abdominal cancer surgery in the very elderly. J Surg Oncol 1991; 47 :82-86.
6. Verdecchia A, Micheli A, Colonna M, Moreno V, Izarzugaza MI, Paci E, EUROPREVAL Working Group. A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Ann Oncol 2002; 13:1128-1139.
7. Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T, et al. Cancer prevalence in European registry areas. Ann Oncol 2002; 13 :840-865.
8. Audisio RA, Bozzetti F, Gennari R, Jaklitsch MT, Koperna T, Longo WE, et al. Surgical management of elderly cancer patients; recommendations of SIOG surgical task force. Eur J Cancer 2004; 40:926-938.
9. Adams J, Audisio AR, White M, Forman D. Age-related variations in progression of cancer at diagnosis and completeness of cancer registry data. Surg Oncol 2004; 13:175-179.
10. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA 1986; 255:3385-3390. (Pubitemid 16080858)
11. Bruce C, Osman N, Audisio RA, Aapro MS. European school of oncology advanced course on cancer in the elderly Liverpool, 29-30 April 2004. Surg Oncol 2004; 13:159-167.
12. Testori A, Stanganelli I, Della Grazia L, Mahadavan L. Diagnosis of Melanoma in the elderly and surgical implications. Surg Oncol 2004; 13 :211-221.
13. Zabrodsky M, Calabrese L, Tosoni A, Ansarin M, Giugliano G, Bruschini R, et al. Major surgery in elderly head and neck cancer patients: immediate and long-term results and complications rates. Surg Oncol 2004; 13 :249-255.
14. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27 :387-404.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
16. Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The national institute on aging and the national cancer institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74 (Suppl):S2101-S2106.
17. American Society of Anesthesiologists. New Classification of physical status. Anesthesiology 1963; 24:111.
18. Leung JM, Dzankic S. Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients. J Am Geriatr Soc 2001; 49:1080-1085.
19. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36:453-471.
20. Hanrahan PF, Hersey P, D'Este CA. Factors involved in presentation of older people with thick melanoma. Med J Aust 1998; 169:410-414.
21. Kelly JW. Melanoma in the elderly - a neglected public health challenge. Med J Aust 1998; 169:403-404.
22. Giles G, Thursfield V. Trends in skin cancer in Australia. Cancer Forum 1996; 20:188-191.
23. MacKie RM, Hole D, Hunter JA, Rankin R, Evans A, McLaren K, et al. Cutaneous malignant melanoma in scotland: incidence, survival and mortality, 1979-1994. BMJ 1997; 315:1117-1121.
24. Chang CK, Jacobs IA, Vizgirda VM, Salti GI. Melanoma in the elderly patient. Arch Surg 2003; 138:1135-1138.
25. MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol 2000; 25:471-475.
26. Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002; 138:609-614.
27. Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. J Am Acad Dermatol 2003; 48:694-701.
28. Veronesi U, Testori A. M. Diagnosis and specialist treatment. Milan: Masson; 2001.
29. Crawson AN, Magro CM, Mihm MC Jr. The melanocytic proliferations. New York: Wiley-Liss; 2001.
30. Stolz W, Braun-Falco O, Bilek P. Color atlas of dermatoscopy. Berlin: Blackwell; 2002.
31. Argenziano G, Soyer HP, De Giorgi V, Piccolo D, Carli P, Delfino M, et al. Interactive atlas of dermoscopy. Milan: Edra Medical Publishing and New Media; 2000.
32. Stanganelli I, Zago S, Testori A, Sforzini F, Zannetti G, Bucchi L. Epiluminescence microscopy features of melanoma in relation to tumour thickness. Dermatol Clin 2001; 19:285-297.
33. Stanganelli I, Pizzichetta MA. Dermoscopy on line.2001. Rabinovitz H, Wells MJ, Oakley A, Gelfand JM, Elston DM, editors. www.emedicine.com
34. Pizzichetta M, Talamini R, Stanganelli I, Puddu P, Bono R, Argenziano G, et al. Amelanotic/hypomelanotic melanoma clinical and dermoscopic features. Br J Dermatol 2004; 150:1117-1124.
35. Chamberlain AJ, Kelly JW. Nodular melanomas and older man: a major challenge for community surveillance programs. Med J Aust 2004; 180:432.
36. Levine J, Kopf AW, Rigel DS, Bart RS, Hennessey P, Friedman RJ, et al. Correlation of thicknesses of superficial spreading malignant melanomas and ages of patients. J Dermatol Surg Oncol 1981; 7: 311-316.
37. Balch CM, Soong SJ, Gershenwald JE, Thompson KF, Reitgen DS, Cascinelli N, et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
38. Loggie B, Ronan SG, Bean J, Das Gupta TK. Invasive cutaneous melanoma in elderly patients. Arch Dermatol 1991; 8:1188-1193.
39. Chao C, Martin RC, Ross MI, Reitgen DS, Edwards MJ, Noyes RD, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004; 11:259-264.
40. Chang AE, Karnell LH, Menck HR. The National Cancer Database report on cutaneous and non-cutaneous melanoma: a summary of 84 836 cases from the past decade. Cancer 1998; 83:1664-1678.
41. Jaroszewski DE, Pockaj BA, Di Caudo DJ, Bite U. The clinical behaviour of desmoplastic melanoma. Am J Surg 2001; 182:590-595.
42. Rivers JK, Kelly MC, Kopf AW, Welkovich B, Bart RS. Age and malignant melanoma: comparison of variables in different age-groups. J Am Acad Dermatol 1989; 21:717-722.
43. Guitart J, Lowe L, Piepkorn M, Prieto VG, Rabkin MS, Ronan SG, et al. Histopathological characteristic of metastasizing thin melanomas: a case control study of 43 cases. Arch Dermatol 2002; 138:603-608.
44. Demierre MF. Thin melanomas and regression, thick melanomas and older men: prognostic implications and perspectives on secondary prevention. Arch Dermatol 2002; 138:678-682.
45. Marks R, Jolley D, McCormack C, Dorevitch AP. Who removes pigmented skin lesions? J Am Acad Dermatol 1997; 36:721-726.
46. English D, Del Mar C, Burton RC. Factors influencing the number needed to excise: excision rates of pigmented lesions by general practitioner. Med J Aust 2004; 180:16-19.
47. Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, Ho V. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579-586.
48. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139:282-288.
49. Lange JR, Balch CM. Melanoma in older patients. American Society of Clinical Oncology: ASCO Educational Book; 2008.
50. Sunderkotter C, Kalden H, Luger TA. Aging and the skin immune system. Arch Dermatol 1997; 133:1256-1263.
51. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25 :459-463.
52. Cox CE, Dupont E, Whitehead GF, Ebert MD, Nguyen K, Peltz ES, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J 2002; 8:88-91.
53. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, et al. Innovations and challenges in melanoma: summary statement from the first Cambridge Conference. Clin Cancer Res 2006; 12:2291-2296.
54. Muravichick S. Anesthesia for the elderly. In: Miller RD, editor. Anesthesia. New York: Churcill Livingstone; 2000. pp. 2140-2156.
55. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleishmann KE, et al. ACC/AHA Guideline update for perioperative cardiovascular evaluation for noncardiac surgery: report of the American College of Cardiology/American Heart Association. J Am Coll Cardiol 2002; 39 :542-553.
56. Proietti R, Aceto P, De Cosmo G. Anesthesia and concomitant pathologies: anesthesia in the elderly patient. Minerva Anesthesiol 2004; 70 :273-278.
57. Whooley BP, Wallack MK. Surgical management of melanoma. Surg Oncol 1995; 4:187-195.
58. Ross MI. Surgery and other local-regional modalities for all stages of melanoma. Curr Opin Oncol 1994; 6:197-201.
59. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet 1907; 1:927-935.
60. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Onc 2001; 8:101-108.
61. Thomas JM, Newton-Bishop J, A'Hern R, Coombes G, Timmons M, Evans J, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350:757-766.
62. Cascinelli N, Van-der Esch EB, Breslow A, Morabito A, Bufalino R. (WHO collaborating centres) Stage I melanoma of the skin the problem of resection margins. Eur J Cancer 1980; 16:1079-1085.
63. Veronesi U, Cascinelli N. Narrow excision (1-cm margin) a safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126:438-441.
64. Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89:1495-1501.
65. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (> 4 mm) primary melanoma. Ann Surg Oncol 1998; 5:322-328.
66. Nitsche N, Hoffmann K, Iro H. Ultrasound diagnosis of skin tumors. HNO 1992; 40:97-100.
67. Kapteijn BA, Nieweg OE, Liem I, Mooi WJ, Balm AJ, Muller SH, et al. Localising the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997; 4:156-160. (Pubitemid 127729059)
68. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
69. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-1491.
70. Ruiter DJ, Testori A, Eggermont AM, Punt CJ. The AJCC staging proposal for cutaneous melanoma: comments by the EORTC melanoma group. Ann Oncol 2001; 12:9-11.
71. Morton DL, Wen DR, Cochran AJ. Management of early stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy an alternative to routine lymphoadenectomy or watch and wait. Surg Oncol Clin North Am 1992; 1:247-259.
72. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel node in a feline model. Ann Surg 1991; 214:637-641.
73. Wong JH, Truelove K, Ko P, Coel MN. Localization and resection of an in transit sentinel lymph node by use of lymphoscintigraphy, intraoperative lymphatic mapping, and a hand-held gamma probe. Surgery 1996; 1 :114-116.
74. Bartolomei M, Testori A, Chinol M, Gennari R, De Cicco C, Leonardi L, et al. Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Eur J Nucl Med 1998; 25:1489-1494.
75. Godellas CV, Berman CG, Lyman G, Cruse CW, Rapaport D, Heller R, et al. The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. Am Surg 1995; 61:97-101.
76. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130:654-658.
77. Van der Veen H, Hoekstra OS, Paul MA, Cuesta MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994; 81:1769-1770.
78. Azzola MF, Shaw HM, Thompson JF, Seng-jaw Soong, Scolyer RA, Watson GF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-1498.
79. Francken AB, Shaw HM, Thompson JF, Seng-jaw Soong, Accortt NA, Azzola MF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11:426-433.
80. Gimotty PA, Elder DE, Fraker DL, Jeffrey B, Kimberly S, Rosalie E, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25:1129-1134.
81. Sassen S, Shaw HM, Colman MH, Scolyer RA, Thompson JF. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. Ann Surg Oncol 2008; 15:630-637. [Epub 2007 Dec 14]
82. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230:453-465. (Pubitemid 30191840)
83. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic. J Cutan Pathol 2005; 32:268-273.
84. McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86:212-213.
85. Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242:302-313.
86. Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R, Multicenter Selective Lymphadenectomy Trial Group. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma [abstract 7500]. J Clin Oncol 2005; 23 (Suppl):S710.
87. Chao C, Martin RC 2nd, Ross MI, Reintgen DS, Edwards MJ, Noyes RD, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004; 11:236-237.
88. Kretschmer L, Thoms KM, Peeters S, Haenssle H, Bertsch HP, Emmert S. Postoperative morbidity of lymph node excision for cutaneous melanoma- sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 2008; 18:16-21.
89. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004; 22 :3677-3684.
90. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
91. Testori A, Bartolomei M, Grana C. Sentinel node localisation in primary melanoma: learning curve and results. Melanoma Res 1999; 9:587-593.
92. Thompson JF, McCarthy WH, Bosch CMJ, O'Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5:255-260.
93. Leong SP, Steinmetz I, Habib FA, McMillan A, Gans JZ, Allen RE Jr, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997; 5:666-673.
94. Karakousis CP, Najibi S, Trunk J. Sentinel node biopsy in malignant melanoma. J Surg Oncol 1997; 66:282-284.
95. Lingam MK, Mackie RM, Mackay AJ. Intraoperative lymphatic mapping using patent blue V dye to identify nodal micrometastases in malignant melanoma. Reg Cancer Treat 1994; 7:144-146.
96. Pijpers R, Collet GJ, Meijer S, Hoekstra OS. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 1995; 22:1238-1241.
97. Testori A. Sentinel node biopsy (SNB) was proposed to stage epidermoid cancer of the male genitals. Melanoma Res 1999; 9:619-620.
98. Testori A, Baldini F, Pelliccia L. Sentinel node biopsy on melanoma patients under local anaesthesia is it worthwhile? Eur J Cancer 2001; 37 (Suppl):S115-S116.
99. Wells KE, Rapaport DP, Cruse CW, Payne W, Albertini J, Berman C, et al. Sentinel lymph node biopsy in melanoma of the head and neck. Plast Reconstr Surg 1997; 100:591-594.
100. Rivers JK, Roof MI. Sentinel lymph-node biopsy in melanoma: is less surgery better? Lancet 1997; 8:1336-1337.
101. Krag D, Harlow S, Weaver D, Ashikaga T. Technique of sentinel node resection in melanoma and breast cancer: probe-guided surgery and lymphatic mapping. Eur J Surg Oncol 1998; 2:89-93.
102. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol 2000; 7:469-474. (Pubitemid 30439307)
103. Gennari R, Bartolomei M, Testori A, Zurrida S, Stoldt HS, Audisio RA, et al. Sentinel node localization in primary melanoma preoperative dynamic lymphoscintigraphy, intraoperative gamma probe and vital dye guidance. Surgery 1999; 127:19-25.
104. Emilia JC, Lawrence W Jr. Sentinel lymph node biopsy in malignant melanoma: the standard of care? J Surg Oncol 1997; 65:153-154.
105. Hochwald S, Coit DG. Role of elective lymph node dissection in melanoma. Semin Surg Oncol 1998; 14:276-282.
106. Balch C, Soong CJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224:255-266.
107. Veronesi U, Adamus J, Bandiera DC, Brennhoud O, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420-2430.
108. Veronesi U, Adamus J, Bandiera DC, Brennhoud O, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297:627-630.
109. Veronesi U, Adamus J, Bandiera DC, Brennhoud O, Caceres E, Cascinelli N, et al. Stage I melanoma of the limbs immediate versus delayed node dissection. Tumori 1980; 66:373-396.
110. Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: the emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9 :219-223.
111. Ross MI. Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Semin Surg Oncol 1996; 12 :394-401.
112. Papachristou D, Fortner JG. Comparison of lymphedema following incontinuity and discontinuity groin dissection. Ann Surg 1977; 185:13-16.
113. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
114. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006; 19:19-25.
115. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15:45-51.
116. Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. Gen Pharmacol 1996; 27:745-748. (Pubitemid 26295629)
117. Aapro MS. Advances in systemic treatment of malignant melanoma. Eur J Cancer 1993; 29:613-617.
118. Ho RC. Medical management of stage IV malignant melanoma medical issues. Cancer 1995; 75:735-741.
119. Fletcher WS, Daniels DS, Sondak VK, Dana B, Townsend R, Hynes HE, et al. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. Am J Clin Oncol 1993; 16:359-362.
120. Hena MA, Emrich LJ, Nambisan RN, Karakousis CP. Effect of surgical treatment on stage IV melanoma. Am J Surg 1987; 153:270-275.
121. Stevens G. Radiation therapy in locally advanced melanoma. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 359-403.
122. Schraffordt Koops H, Lejeune FJ, Kroon BB, Klaase JM, Hoekstra HJ. Isolated limb perfusion: technical aspects. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of Melanoma. London: Martin Dunitz; 2004. pp. 404-409.
123. Kroon BB, Fraker DL, Vrouenraets BC, Thompson JF. Isolated limb perfusion: results and complications. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 410-428.
124. Thompson JF, Kam PCA, De Wilt JHW, Lindner P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 429-437.
125. Smithers BM, De Wilt JHW. Isolated limb perfusion and infusion: preclinical studies and future directions. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 438-442.
126. McKay AJ, Byrne DS. Other treatments. In: Thompson JF, Morton DL, Kroon BB, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 443-448.
127. Noorda EM, Vrouenraets BC, Nieweg OE, Van Geel AN, Eggermont AM, Kroon BB. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002; 9:968-974.
128. Koops HS, Garbe C, Hohenberger P. Is isolated limb perfusion of metastatic malignant melanoma of the extremity worth while? Eur J Cancer 1996; 32:1633-1640. (Pubitemid 26306869)
129. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995; 1 :122-130.
130. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb perfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997; 80:2084-2090.
131. McMasters KM. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002; 9:939-940.
132. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83 :1319-1328.
133. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26:335-349.